nodes	percent_of_prediction	percent_of_DWPC	metapath
Mivacurium—BCHE—Ramipril—type 2 diabetes mellitus	0.318	1	CbGbCtD
Mivacurium—Anaphylactoid reaction—Repaglinide—type 2 diabetes mellitus	0.00696	0.0147	CcSEcCtD
Mivacurium—Erythema—Tolbutamide—type 2 diabetes mellitus	0.00556	0.0117	CcSEcCtD
Mivacurium—Immune system disorder—Linagliptin—type 2 diabetes mellitus	0.0052	0.0109	CcSEcCtD
Mivacurium—Mediastinal disorder—Linagliptin—type 2 diabetes mellitus	0.00519	0.0109	CcSEcCtD
Mivacurium—Angiopathy—Acarbose—type 2 diabetes mellitus	0.00507	0.0107	CcSEcCtD
Mivacurium—Erythema—Tolazamide—type 2 diabetes mellitus	0.00506	0.0107	CcSEcCtD
Mivacurium—Immune system disorder—Acarbose—type 2 diabetes mellitus	0.00505	0.0106	CcSEcCtD
Mivacurium—Immune system disorder—Nateglinide—type 2 diabetes mellitus	0.00487	0.0102	CcSEcCtD
Mivacurium—Erythema—Acarbose—type 2 diabetes mellitus	0.00486	0.0102	CcSEcCtD
Mivacurium—Cardiac disorder—Repaglinide—type 2 diabetes mellitus	0.00433	0.00911	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Linagliptin—type 2 diabetes mellitus	0.00424	0.00891	CcSEcCtD
Mivacurium—Immune system disorder—Repaglinide—type 2 diabetes mellitus	0.00421	0.00886	CcSEcCtD
Mivacurium—Arrhythmia—Repaglinide—type 2 diabetes mellitus	0.00417	0.00876	CcSEcCtD
Mivacurium—Cardiac disorder—Rosiglitazone—type 2 diabetes mellitus	0.00409	0.00861	CcSEcCtD
Mivacurium—Anaphylactic shock—Linagliptin—type 2 diabetes mellitus	0.00409	0.0086	CcSEcCtD
Mivacurium—Wheezing—Irbesartan—type 2 diabetes mellitus	0.00407	0.00857	CcSEcCtD
Mivacurium—Erythema—Repaglinide—type 2 diabetes mellitus	0.00406	0.00854	CcSEcCtD
Mivacurium—Immune system disorder—Rosiglitazone—type 2 diabetes mellitus	0.00398	0.00838	CcSEcCtD
Mivacurium—Skin disorder—Linagliptin—type 2 diabetes mellitus	0.00397	0.00836	CcSEcCtD
Mivacurium—Bradycardia—Glimepiride—type 2 diabetes mellitus	0.00367	0.00771	CcSEcCtD
Mivacurium—Urticaria—Tolbutamide—type 2 diabetes mellitus	0.00361	0.00759	CcSEcCtD
Mivacurium—Flushing—Glipizide—type 2 diabetes mellitus	0.00358	0.00753	CcSEcCtD
Mivacurium—Arrhythmia—Glipizide—type 2 diabetes mellitus	0.00345	0.00725	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Repaglinide—type 2 diabetes mellitus	0.00343	0.00722	CcSEcCtD
Mivacurium—Cardiac disorder—Pioglitazone—type 2 diabetes mellitus	0.00343	0.00722	CcSEcCtD
Mivacurium—Erythema—Glipizide—type 2 diabetes mellitus	0.00336	0.00707	CcSEcCtD
Mivacurium—Immune system disorder—Pioglitazone—type 2 diabetes mellitus	0.00334	0.00702	CcSEcCtD
Mivacurium—Mediastinal disorder—Pioglitazone—type 2 diabetes mellitus	0.00333	0.00701	CcSEcCtD
Mivacurium—Cardiac disorder—Sitagliptin—type 2 diabetes mellitus	0.00333	0.00701	CcSEcCtD
Mivacurium—Anaphylactic shock—Repaglinide—type 2 diabetes mellitus	0.00331	0.00697	CcSEcCtD
Mivacurium—Bradycardia—Bromocriptine—type 2 diabetes mellitus	0.00331	0.00696	CcSEcCtD
Mivacurium—Urticaria—Chlorpropamide—type 2 diabetes mellitus	0.00328	0.00691	CcSEcCtD
Mivacurium—Urticaria—Tolazamide—type 2 diabetes mellitus	0.00328	0.00691	CcSEcCtD
Mivacurium—Angiopathy—Sitagliptin—type 2 diabetes mellitus	0.00326	0.00685	CcSEcCtD
Mivacurium—Urticaria—Linagliptin—type 2 diabetes mellitus	0.00325	0.00683	CcSEcCtD
Mivacurium—Immune system disorder—Sitagliptin—type 2 diabetes mellitus	0.00324	0.00682	CcSEcCtD
Mivacurium—Mediastinal disorder—Sitagliptin—type 2 diabetes mellitus	0.00323	0.00681	CcSEcCtD
Mivacurium—Muscle spasms—Glipizide—type 2 diabetes mellitus	0.00323	0.00679	CcSEcCtD
Mivacurium—Skin disorder—Repaglinide—type 2 diabetes mellitus	0.00322	0.00677	CcSEcCtD
Mivacurium—Arrhythmia—Glimepiride—type 2 diabetes mellitus	0.00322	0.00677	CcSEcCtD
Mivacurium—Rash—Miglitol—type 2 diabetes mellitus	0.00318	0.0067	CcSEcCtD
Mivacurium—Dermatitis—Miglitol—type 2 diabetes mellitus	0.00318	0.00669	CcSEcCtD
Mivacurium—Urticaria—Acarbose—type 2 diabetes mellitus	0.00315	0.00663	CcSEcCtD
Mivacurium—Erythema—Glimepiride—type 2 diabetes mellitus	0.00313	0.00659	CcSEcCtD
Mivacurium—Anaphylactic shock—Rosiglitazone—type 2 diabetes mellitus	0.00313	0.00659	CcSEcCtD
Mivacurium—Muscle spasms—Pioglitazone—type 2 diabetes mellitus	0.00309	0.00651	CcSEcCtD
Mivacurium—Urticaria—Nateglinide—type 2 diabetes mellitus	0.00304	0.0064	CcSEcCtD
Mivacurium—Cardiac disorder—Bromocriptine—type 2 diabetes mellitus	0.00301	0.00634	CcSEcCtD
Mivacurium—Muscle spasms—Sitagliptin—type 2 diabetes mellitus	0.003	0.00632	CcSEcCtD
Mivacurium—Bronchospasm—Orlistat—type 2 diabetes mellitus	0.00297	0.00626	CcSEcCtD
Mivacurium—Angiopathy—Bromocriptine—type 2 diabetes mellitus	0.00295	0.0062	CcSEcCtD
Mivacurium—Mediastinal disorder—Bromocriptine—type 2 diabetes mellitus	0.00293	0.00616	CcSEcCtD
Mivacurium—Arrhythmia—Bromocriptine—type 2 diabetes mellitus	0.0029	0.0061	CcSEcCtD
Mivacurium—Rash—Tolbutamide—type 2 diabetes mellitus	0.00286	0.00602	CcSEcCtD
Mivacurium—Dizziness—Tolazamide—type 2 diabetes mellitus	0.00273	0.00575	CcSEcCtD
Mivacurium—Dizziness—Chlorpropamide—type 2 diabetes mellitus	0.00273	0.00575	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Pioglitazone—type 2 diabetes mellitus	0.00272	0.00572	CcSEcCtD
Mivacurium—Muscle spasms—Bromocriptine—type 2 diabetes mellitus	0.00272	0.00572	CcSEcCtD
Mivacurium—Bradycardia—Gliclazide—type 2 diabetes mellitus	0.00271	0.00571	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Sitagliptin—type 2 diabetes mellitus	0.00264	0.00556	CcSEcCtD
Mivacurium—Urticaria—Repaglinide—type 2 diabetes mellitus	0.00263	0.00554	CcSEcCtD
Mivacurium—Anaphylactic shock—Pioglitazone—type 2 diabetes mellitus	0.00263	0.00552	CcSEcCtD
Mivacurium—Rash—Chlorpropamide—type 2 diabetes mellitus	0.00261	0.00548	CcSEcCtD
Mivacurium—Rash—Tolazamide—type 2 diabetes mellitus	0.00261	0.00548	CcSEcCtD
Mivacurium—Erythema—Glyburide—type 2 diabetes mellitus	0.00258	0.00544	CcSEcCtD
Mivacurium—Rash—Linagliptin—type 2 diabetes mellitus	0.00258	0.00542	CcSEcCtD
Mivacurium—Dermatitis—Linagliptin—type 2 diabetes mellitus	0.00258	0.00542	CcSEcCtD
Mivacurium—Anaphylactic shock—Glimepiride—type 2 diabetes mellitus	0.00256	0.00538	CcSEcCtD
Mivacurium—Skin disorder—Pioglitazone—type 2 diabetes mellitus	0.00255	0.00537	CcSEcCtD
Mivacurium—Anaphylactic shock—Sitagliptin—type 2 diabetes mellitus	0.00255	0.00536	CcSEcCtD
Mivacurium—Anaphylactoid reaction—Ramipril—type 2 diabetes mellitus	0.00254	0.00534	CcSEcCtD
Mivacurium—Dizziness—Nateglinide—type 2 diabetes mellitus	0.00253	0.00533	CcSEcCtD
Mivacurium—Rash—Acarbose—type 2 diabetes mellitus	0.0025	0.00527	CcSEcCtD
Mivacurium—Dermatitis—Acarbose—type 2 diabetes mellitus	0.0025	0.00526	CcSEcCtD
Mivacurium—Tachycardia—Glimepiride—type 2 diabetes mellitus	0.0025	0.00525	CcSEcCtD
Mivacurium—Urticaria—Rosiglitazone—type 2 diabetes mellitus	0.00249	0.00523	CcSEcCtD
Mivacurium—Skin disorder—Sitagliptin—type 2 diabetes mellitus	0.00248	0.00521	CcSEcCtD
Mivacurium—Flushing—Gliclazide—type 2 diabetes mellitus	0.00247	0.00521	CcSEcCtD
Mivacurium—Rash—Nateglinide—type 2 diabetes mellitus	0.00241	0.00508	CcSEcCtD
Mivacurium—Dermatitis—Nateglinide—type 2 diabetes mellitus	0.00241	0.00507	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Bromocriptine—type 2 diabetes mellitus	0.00239	0.00503	CcSEcCtD
Mivacurium—Hypotension—Glimepiride—type 2 diabetes mellitus	0.00239	0.00503	CcSEcCtD
Mivacurium—Arrhythmia—Gliclazide—type 2 diabetes mellitus	0.00238	0.00501	CcSEcCtD
Mivacurium—Erythema—Gliclazide—type 2 diabetes mellitus	0.00232	0.00488	CcSEcCtD
Mivacurium—Cardiac disorder—Valsartan—type 2 diabetes mellitus	0.00227	0.00478	CcSEcCtD
Mivacurium—Bradycardia—Metformin—type 2 diabetes mellitus	0.00227	0.00478	CcSEcCtD
Mivacurium—Tachycardia—Bromocriptine—type 2 diabetes mellitus	0.00225	0.00474	CcSEcCtD
Mivacurium—Skin disorder—Bromocriptine—type 2 diabetes mellitus	0.00224	0.00472	CcSEcCtD
Mivacurium—Angiopathy—Valsartan—type 2 diabetes mellitus	0.00222	0.00468	CcSEcCtD
Mivacurium—Immune system disorder—Valsartan—type 2 diabetes mellitus	0.00221	0.00466	CcSEcCtD
Mivacurium—Mediastinal disorder—Valsartan—type 2 diabetes mellitus	0.00221	0.00464	CcSEcCtD
Mivacurium—Immune system disorder—Orlistat—type 2 diabetes mellitus	0.00219	0.0046	CcSEcCtD
Mivacurium—Mediastinal disorder—Orlistat—type 2 diabetes mellitus	0.00218	0.00459	CcSEcCtD
Mivacurium—Urticaria—Glipizide—type 2 diabetes mellitus	0.00218	0.00458	CcSEcCtD
Mivacurium—Hypotension—Bromocriptine—type 2 diabetes mellitus	0.00216	0.00454	CcSEcCtD
Mivacurium—Bradycardia—Irbesartan—type 2 diabetes mellitus	0.00214	0.00451	CcSEcCtD
Mivacurium—Rash—Repaglinide—type 2 diabetes mellitus	0.00209	0.00439	CcSEcCtD
Mivacurium—Bronchospasm—Ramipril—type 2 diabetes mellitus	0.00209	0.00439	CcSEcCtD
Mivacurium—Dermatitis—Repaglinide—type 2 diabetes mellitus	0.00209	0.00439	CcSEcCtD
Mivacurium—Urticaria—Pioglitazone—type 2 diabetes mellitus	0.00209	0.00439	CcSEcCtD
Mivacurium—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.00207	0.00436	CcSEcCtD
Mivacurium—Flushing—Metformin—type 2 diabetes mellitus	0.00207	0.00436	CcSEcCtD
Mivacurium—Cardiac disorder—Metformin—type 2 diabetes mellitus	0.00207	0.00436	CcSEcCtD
Mivacurium—Muscle spasms—Valsartan—type 2 diabetes mellitus	0.00205	0.00431	CcSEcCtD
Mivacurium—Urticaria—Glimepiride—type 2 diabetes mellitus	0.00203	0.00428	CcSEcCtD
Mivacurium—Muscle spasms—Orlistat—type 2 diabetes mellitus	0.00203	0.00426	CcSEcCtD
Mivacurium—Urticaria—Sitagliptin—type 2 diabetes mellitus	0.00203	0.00426	CcSEcCtD
Mivacurium—Angiopathy—Metformin—type 2 diabetes mellitus	0.00202	0.00426	CcSEcCtD
Mivacurium—Immune system disorder—Metformin—type 2 diabetes mellitus	0.00201	0.00424	CcSEcCtD
Mivacurium—Mediastinal disorder—Metformin—type 2 diabetes mellitus	0.00201	0.00423	CcSEcCtD
Mivacurium—Rash—Rosiglitazone—type 2 diabetes mellitus	0.00197	0.00415	CcSEcCtD
Mivacurium—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.00197	0.00415	CcSEcCtD
Mivacurium—Hypotension—Glyburide—type 2 diabetes mellitus	0.00197	0.00415	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Gliclazide—type 2 diabetes mellitus	0.00196	0.00413	CcSEcCtD
Mivacurium—Flushing—Irbesartan—type 2 diabetes mellitus	0.00195	0.00411	CcSEcCtD
Mivacurium—Cardiac disorder—Irbesartan—type 2 diabetes mellitus	0.00195	0.00411	CcSEcCtD
Mivacurium—Erythema—Metformin—type 2 diabetes mellitus	0.00194	0.00409	CcSEcCtD
Mivacurium—Angiopathy—Irbesartan—type 2 diabetes mellitus	0.00191	0.00402	CcSEcCtD
Mivacurium—Immune system disorder—Irbesartan—type 2 diabetes mellitus	0.0019	0.004	CcSEcCtD
Mivacurium—Mediastinal disorder—Irbesartan—type 2 diabetes mellitus	0.0019	0.00399	CcSEcCtD
Mivacurium—Arrhythmia—Irbesartan—type 2 diabetes mellitus	0.00188	0.00396	CcSEcCtD
Mivacurium—Muscle spasms—Metformin—type 2 diabetes mellitus	0.00187	0.00393	CcSEcCtD
Mivacurium—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.00185	0.00389	CcSEcCtD
Mivacurium—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.00184	0.00387	CcSEcCtD
Mivacurium—Flushing—Losartan—type 2 diabetes mellitus	0.00184	0.00387	CcSEcCtD
Mivacurium—Urticaria—Bromocriptine—type 2 diabetes mellitus	0.00183	0.00386	CcSEcCtD
Mivacurium—Erythema—Irbesartan—type 2 diabetes mellitus	0.00183	0.00386	CcSEcCtD
Mivacurium—Dizziness—Glipizide—type 2 diabetes mellitus	0.00181	0.00381	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.0018	0.00379	CcSEcCtD
Mivacurium—Angiopathy—Losartan—type 2 diabetes mellitus	0.0018	0.00378	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.00178	0.00375	CcSEcCtD
Mivacurium—Hypotension—Gliclazide—type 2 diabetes mellitus	0.00177	0.00372	CcSEcCtD
Mivacurium—Arrhythmia—Losartan—type 2 diabetes mellitus	0.00177	0.00372	CcSEcCtD
Mivacurium—Muscle spasms—Irbesartan—type 2 diabetes mellitus	0.00176	0.00371	CcSEcCtD
Mivacurium—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	0.00174	0.00366	CcSEcCtD
Mivacurium—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.00174	0.00365	CcSEcCtD
Mivacurium—Rash—Glipizide—type 2 diabetes mellitus	0.00173	0.00364	CcSEcCtD
Mivacurium—Dermatitis—Glipizide—type 2 diabetes mellitus	0.00173	0.00363	CcSEcCtD
Mivacurium—Erythema—Losartan—type 2 diabetes mellitus	0.00172	0.00363	CcSEcCtD
Mivacurium—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	0.00172	0.00362	CcSEcCtD
Mivacurium—Dizziness—Glimepiride—type 2 diabetes mellitus	0.00169	0.00356	CcSEcCtD
Mivacurium—Skin disorder—Valsartan—type 2 diabetes mellitus	0.00169	0.00356	CcSEcCtD
Mivacurium—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.00169	0.00355	CcSEcCtD
Mivacurium—Urticaria—Glyburide—type 2 diabetes mellitus	0.00168	0.00353	CcSEcCtD
Mivacurium—Skin disorder—Orlistat—type 2 diabetes mellitus	0.00167	0.00351	CcSEcCtD
Mivacurium—Muscle spasms—Losartan—type 2 diabetes mellitus	0.00166	0.00349	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.00164	0.00345	CcSEcCtD
Mivacurium—Hypotension—Valsartan—type 2 diabetes mellitus	0.00163	0.00342	CcSEcCtD
Mivacurium—Rash—Glimepiride—type 2 diabetes mellitus	0.00161	0.00339	CcSEcCtD
Mivacurium—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.00161	0.00339	CcSEcCtD
Mivacurium—Rash—Sitagliptin—type 2 diabetes mellitus	0.00161	0.00338	CcSEcCtD
Mivacurium—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.00161	0.00338	CcSEcCtD
Mivacurium—Flushing—Ramipril—type 2 diabetes mellitus	0.00158	0.00332	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.00155	0.00326	CcSEcCtD
Mivacurium—Skin disorder—Metformin—type 2 diabetes mellitus	0.00154	0.00324	CcSEcCtD
Mivacurium—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.00153	0.00323	CcSEcCtD
Mivacurium—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.00153	0.00322	CcSEcCtD
Mivacurium—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.00153	0.00321	CcSEcCtD
Mivacurium—Arrhythmia—Ramipril—type 2 diabetes mellitus	0.00152	0.00319	CcSEcCtD
Mivacurium—Urticaria—Gliclazide—type 2 diabetes mellitus	0.0015	0.00317	CcSEcCtD
Mivacurium—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.0015	0.00315	CcSEcCtD
Mivacurium—Hypotension—Metformin—type 2 diabetes mellitus	0.00148	0.00312	CcSEcCtD
Mivacurium—Erythema—Ramipril—type 2 diabetes mellitus	0.00148	0.00311	CcSEcCtD
Mivacurium—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.00146	0.00307	CcSEcCtD
Mivacurium—Rash—Bromocriptine—type 2 diabetes mellitus	0.00146	0.00306	CcSEcCtD
Mivacurium—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.00145	0.00306	CcSEcCtD
Mivacurium—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.00145	0.00306	CcSEcCtD
Mivacurium—Muscle spasms—Ramipril—type 2 diabetes mellitus	0.00142	0.00299	CcSEcCtD
Mivacurium—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.00141	0.00296	CcSEcCtD
Mivacurium—Hypotension—Irbesartan—type 2 diabetes mellitus	0.0014	0.00294	CcSEcCtD
Mivacurium—Urticaria—Valsartan—type 2 diabetes mellitus	0.00138	0.00291	CcSEcCtD
Mivacurium—Tachycardia—Losartan—type 2 diabetes mellitus	0.00137	0.00289	CcSEcCtD
Mivacurium—Urticaria—Orlistat—type 2 diabetes mellitus	0.00137	0.00287	CcSEcCtD
Mivacurium—Rash—Glyburide—type 2 diabetes mellitus	0.00133	0.0028	CcSEcCtD
Mivacurium—Dermatitis—Glyburide—type 2 diabetes mellitus	0.00133	0.0028	CcSEcCtD
Mivacurium—Hypotension—Losartan—type 2 diabetes mellitus	0.00132	0.00277	CcSEcCtD
Mivacurium—Urticaria—Metformin—type 2 diabetes mellitus	0.00126	0.00265	CcSEcCtD
Mivacurium—Dizziness—Gliclazide—type 2 diabetes mellitus	0.00125	0.00264	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.00125	0.00263	CcSEcCtD
Mivacurium—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.00121	0.00254	CcSEcCtD
Mivacurium—Rash—Gliclazide—type 2 diabetes mellitus	0.00119	0.00251	CcSEcCtD
Mivacurium—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.00119	0.00251	CcSEcCtD
Mivacurium—Urticaria—Irbesartan—type 2 diabetes mellitus	0.00119	0.0025	CcSEcCtD
Mivacurium—Tachycardia—Ramipril—type 2 diabetes mellitus	0.00118	0.00248	CcSEcCtD
Mivacurium—Skin disorder—Ramipril—type 2 diabetes mellitus	0.00117	0.00247	CcSEcCtD
Mivacurium—Dizziness—Valsartan—type 2 diabetes mellitus	0.00115	0.00242	CcSEcCtD
Mivacurium—Dizziness—Orlistat—type 2 diabetes mellitus	0.00114	0.00239	CcSEcCtD
Mivacurium—Hypotension—Ramipril—type 2 diabetes mellitus	0.00113	0.00237	CcSEcCtD
Mivacurium—Urticaria—Losartan—type 2 diabetes mellitus	0.00112	0.00235	CcSEcCtD
Mivacurium—Rash—Valsartan—type 2 diabetes mellitus	0.0011	0.00231	CcSEcCtD
Mivacurium—Dermatitis—Valsartan—type 2 diabetes mellitus	0.0011	0.00231	CcSEcCtD
Mivacurium—Rash—Orlistat—type 2 diabetes mellitus	0.00108	0.00228	CcSEcCtD
Mivacurium—Dermatitis—Orlistat—type 2 diabetes mellitus	0.00108	0.00228	CcSEcCtD
Mivacurium—Dizziness—Metformin—type 2 diabetes mellitus	0.00105	0.0022	CcSEcCtD
Mivacurium—Rash—Metformin—type 2 diabetes mellitus	0.000999	0.0021	CcSEcCtD
Mivacurium—Dermatitis—Metformin—type 2 diabetes mellitus	0.000998	0.0021	CcSEcCtD
Mivacurium—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000989	0.00208	CcSEcCtD
Mivacurium—Urticaria—Ramipril—type 2 diabetes mellitus	0.000959	0.00202	CcSEcCtD
Mivacurium—Rash—Irbesartan—type 2 diabetes mellitus	0.000943	0.00198	CcSEcCtD
Mivacurium—Dermatitis—Irbesartan—type 2 diabetes mellitus	0.000942	0.00198	CcSEcCtD
Mivacurium—Dizziness—Losartan—type 2 diabetes mellitus	0.000931	0.00196	CcSEcCtD
Mivacurium—Rash—Losartan—type 2 diabetes mellitus	0.000887	0.00187	CcSEcCtD
Mivacurium—Dermatitis—Losartan—type 2 diabetes mellitus	0.000887	0.00187	CcSEcCtD
Mivacurium—Dizziness—Ramipril—type 2 diabetes mellitus	0.000798	0.00168	CcSEcCtD
Mivacurium—Rash—Ramipril—type 2 diabetes mellitus	0.000761	0.0016	CcSEcCtD
Mivacurium—Dermatitis—Ramipril—type 2 diabetes mellitus	0.00076	0.0016	CcSEcCtD
Mivacurium—CHRM3—Metabolism—NAMPT—type 2 diabetes mellitus	5.85e-05	0.000283	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—LIPC—type 2 diabetes mellitus	5.81e-05	0.000282	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—HBA1—type 2 diabetes mellitus	5.81e-05	0.000282	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—GCK—type 2 diabetes mellitus	5.81e-05	0.000282	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CYP11A1—type 2 diabetes mellitus	5.78e-05	0.00028	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—EDN1—type 2 diabetes mellitus	5.7e-05	0.000276	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—SLC9A1—type 2 diabetes mellitus	5.67e-05	0.000275	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	5.65e-05	0.000274	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—EDN1—type 2 diabetes mellitus	5.64e-05	0.000273	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CETP—type 2 diabetes mellitus	5.61e-05	0.000272	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	5.6e-05	0.000271	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—SPRY2—type 2 diabetes mellitus	5.6e-05	0.000271	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	5.59e-05	0.000271	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—SPRY2—type 2 diabetes mellitus	5.54e-05	0.000269	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	5.54e-05	0.000269	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—GNB3—type 2 diabetes mellitus	5.51e-05	0.000267	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—GNB3—type 2 diabetes mellitus	5.46e-05	0.000265	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—RBP4—type 2 diabetes mellitus	5.45e-05	0.000264	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—GLP1R—type 2 diabetes mellitus	5.45e-05	0.000264	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—MMP3—type 2 diabetes mellitus	5.44e-05	0.000264	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—AVP—type 2 diabetes mellitus	5.44e-05	0.000264	CbGpPWpGaD
Mivacurium—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—type 2 diabetes mellitus	5.43e-05	0.000263	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	5.41e-05	0.000262	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—GLP1R—type 2 diabetes mellitus	5.4e-05	0.000262	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—RBP4—type 2 diabetes mellitus	5.4e-05	0.000262	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—AVP—type 2 diabetes mellitus	5.39e-05	0.000261	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—MMP3—type 2 diabetes mellitus	5.39e-05	0.000261	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CCKAR—type 2 diabetes mellitus	5.36e-05	0.00026	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	5.36e-05	0.00026	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CCKAR—type 2 diabetes mellitus	5.31e-05	0.000257	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PSMD6—type 2 diabetes mellitus	5.21e-05	0.000253	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—SNAP25—type 2 diabetes mellitus	5.21e-05	0.000253	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—SREBF1—type 2 diabetes mellitus	5.21e-05	0.000253	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—EDN1—type 2 diabetes mellitus	5.17e-05	0.000251	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—EDN1—type 2 diabetes mellitus	5.12e-05	0.000248	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CTGF—type 2 diabetes mellitus	5.12e-05	0.000248	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	5.09e-05	0.000247	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—HMGCR—type 2 diabetes mellitus	5.07e-05	0.000246	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—GNB3—type 2 diabetes mellitus	5.07e-05	0.000246	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.07e-05	0.000246	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	5.04e-05	0.000244	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—HMOX1—type 2 diabetes mellitus	5.04e-05	0.000244	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—C3—type 2 diabetes mellitus	4.98e-05	0.000241	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—CAT—type 2 diabetes mellitus	4.98e-05	0.000241	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ADRA2A—type 2 diabetes mellitus	4.96e-05	0.000241	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—C3—type 2 diabetes mellitus	4.93e-05	0.000239	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	4.92e-05	0.000238	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	4.87e-05	0.000236	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	4.86e-05	0.000236	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—APOB—type 2 diabetes mellitus	4.83e-05	0.000234	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—IAPP—type 2 diabetes mellitus	4.83e-05	0.000234	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	4.81e-05	0.000233	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—INSR—type 2 diabetes mellitus	4.8e-05	0.000233	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—IAPP—type 2 diabetes mellitus	4.78e-05	0.000232	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CYP2E1—type 2 diabetes mellitus	4.77e-05	0.000231	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—INSR—type 2 diabetes mellitus	4.75e-05	0.00023	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—AGT—type 2 diabetes mellitus	4.73e-05	0.000229	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—TRPC6—type 2 diabetes mellitus	4.72e-05	0.000229	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—SLC2A1—type 2 diabetes mellitus	4.71e-05	0.000229	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CYP1A2—type 2 diabetes mellitus	4.71e-05	0.000229	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	4.71e-05	0.000228	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—GSTM1—type 2 diabetes mellitus	4.7e-05	0.000228	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—AGTR2—type 2 diabetes mellitus	4.69e-05	0.000227	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—AGT—type 2 diabetes mellitus	4.68e-05	0.000227	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—TRPC6—type 2 diabetes mellitus	4.67e-05	0.000226	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	4.66e-05	0.000226	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—AGTR2—type 2 diabetes mellitus	4.64e-05	0.000225	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—CCR5—type 2 diabetes mellitus	4.63e-05	0.000224	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—LPL—type 2 diabetes mellitus	4.61e-05	0.000224	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CYP3A4—type 2 diabetes mellitus	4.6e-05	0.000223	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—CCR5—type 2 diabetes mellitus	4.58e-05	0.000222	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—C3—type 2 diabetes mellitus	4.52e-05	0.000219	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—GCG—type 2 diabetes mellitus	4.52e-05	0.000219	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—SLC2A4—type 2 diabetes mellitus	4.52e-05	0.000219	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—ADCY5—type 2 diabetes mellitus	4.52e-05	0.000219	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—GPX1—type 2 diabetes mellitus	4.5e-05	0.000218	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—EDNRB—type 2 diabetes mellitus	4.49e-05	0.000218	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—C3—type 2 diabetes mellitus	4.48e-05	0.000217	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—EDNRB—type 2 diabetes mellitus	4.45e-05	0.000216	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—CD36—type 2 diabetes mellitus	4.38e-05	0.000212	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	4.37e-05	0.000212	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HTR2C—type 2 diabetes mellitus	4.36e-05	0.000211	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PSMD6—type 2 diabetes mellitus	4.36e-05	0.000211	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	4.33e-05	0.00021	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PPP2CA—type 2 diabetes mellitus	4.33e-05	0.00021	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PSMD6—type 2 diabetes mellitus	4.32e-05	0.000209	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HTR2C—type 2 diabetes mellitus	4.32e-05	0.000209	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—AGT—type 2 diabetes mellitus	4.3e-05	0.000208	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—AGT—type 2 diabetes mellitus	4.25e-05	0.000206	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—EDNRA—type 2 diabetes mellitus	4.24e-05	0.000206	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—CALM1—type 2 diabetes mellitus	4.22e-05	0.000205	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CYBA—type 2 diabetes mellitus	4.22e-05	0.000205	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—EDNRA—type 2 diabetes mellitus	4.2e-05	0.000204	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—CALM1—type 2 diabetes mellitus	4.18e-05	0.000203	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CYBA—type 2 diabetes mellitus	4.18e-05	0.000203	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—MTHFR—type 2 diabetes mellitus	4.15e-05	0.000201	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	4.15e-05	0.000201	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—GHRL—type 2 diabetes mellitus	4.13e-05	0.0002	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PLAT—type 2 diabetes mellitus	4.13e-05	0.0002	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	4.11e-05	0.000199	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PLAT—type 2 diabetes mellitus	4.09e-05	0.000198	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—GHRL—type 2 diabetes mellitus	4.09e-05	0.000198	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CALCA—type 2 diabetes mellitus	4.08e-05	0.000198	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PPARA—type 2 diabetes mellitus	4.07e-05	0.000197	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CALCA—type 2 diabetes mellitus	4.04e-05	0.000196	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	3.97e-05	0.000192	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—AGT—type 2 diabetes mellitus	3.95e-05	0.000191	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	3.93e-05	0.00019	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.9e-05	0.000189	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—GNB3—type 2 diabetes mellitus	3.9e-05	0.000189	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—CALM1—type 2 diabetes mellitus	3.88e-05	0.000188	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—HMOX1—type 2 diabetes mellitus	3.88e-05	0.000188	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—APOE—type 2 diabetes mellitus	3.87e-05	0.000187	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	3.84e-05	0.000186	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	3.83e-05	0.000185	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CAT—type 2 diabetes mellitus	3.83e-05	0.000185	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—APOA1—type 2 diabetes mellitus	3.82e-05	0.000185	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	3.81e-05	0.000185	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	3.79e-05	0.000184	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—GCG—type 2 diabetes mellitus	3.78e-05	0.000183	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PTPN1—type 2 diabetes mellitus	3.78e-05	0.000183	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—GCG—type 2 diabetes mellitus	3.74e-05	0.000181	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PTPN1—type 2 diabetes mellitus	3.74e-05	0.000181	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	3.72e-05	0.00018	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—APOB—type 2 diabetes mellitus	3.71e-05	0.00018	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	3.71e-05	0.00018	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	3.68e-05	0.000178	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	3.67e-05	0.000178	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—GSTM1—type 2 diabetes mellitus	3.61e-05	0.000175	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—LPL—type 2 diabetes mellitus	3.55e-05	0.000172	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—CCL2—type 2 diabetes mellitus	3.54e-05	0.000171	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—CCL2—type 2 diabetes mellitus	3.5e-05	0.00017	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—AKT2—type 2 diabetes mellitus	3.47e-05	0.000168	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ADCY5—type 2 diabetes mellitus	3.47e-05	0.000168	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	3.47e-05	0.000168	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—GPX1—type 2 diabetes mellitus	3.46e-05	0.000168	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—AKT2—type 2 diabetes mellitus	3.44e-05	0.000167	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	3.44e-05	0.000167	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CD36—type 2 diabetes mellitus	3.37e-05	0.000163	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PPARG—type 2 diabetes mellitus	3.37e-05	0.000163	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PPP2CA—type 2 diabetes mellitus	3.33e-05	0.000161	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—INS—type 2 diabetes mellitus	3.3e-05	0.00016	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	3.29e-05	0.000159	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—GNB3—type 2 diabetes mellitus	3.26e-05	0.000158	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	3.26e-05	0.000158	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—GNB3—type 2 diabetes mellitus	3.23e-05	0.000156	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—AVP—type 2 diabetes mellitus	3.21e-05	0.000156	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MMP3—type 2 diabetes mellitus	3.21e-05	0.000156	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—IGF2—type 2 diabetes mellitus	3.2e-05	0.000155	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—MTHFR—type 2 diabetes mellitus	3.19e-05	0.000155	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	3.19e-05	0.000154	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MMP3—type 2 diabetes mellitus	3.18e-05	0.000154	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—AVP—type 2 diabetes mellitus	3.18e-05	0.000154	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—IGF2—type 2 diabetes mellitus	3.17e-05	0.000154	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	3.15e-05	0.000153	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	3.15e-05	0.000153	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PPARA—type 2 diabetes mellitus	3.13e-05	0.000152	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	3.12e-05	0.000151	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—APOB—type 2 diabetes mellitus	3.11e-05	0.000151	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—IGF1R—type 2 diabetes mellitus	3.09e-05	0.00015	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—APOB—type 2 diabetes mellitus	3.08e-05	0.000149	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—IGF1R—type 2 diabetes mellitus	3.06e-05	0.000148	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—EDN1—type 2 diabetes mellitus	3.06e-05	0.000148	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—AGT—type 2 diabetes mellitus	3.03e-05	0.000147	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—ALB—type 2 diabetes mellitus	3.03e-05	0.000147	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—EDN1—type 2 diabetes mellitus	3.03e-05	0.000147	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CALM1—type 2 diabetes mellitus	2.98e-05	0.000145	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—APOE—type 2 diabetes mellitus	2.97e-05	0.000144	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—LPL—type 2 diabetes mellitus	2.97e-05	0.000144	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—APOA1—type 2 diabetes mellitus	2.94e-05	0.000142	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—LPL—type 2 diabetes mellitus	2.94e-05	0.000142	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ADCY5—type 2 diabetes mellitus	2.9e-05	0.000141	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PIK3R1—type 2 diabetes mellitus	2.9e-05	0.00014	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—NOS3—type 2 diabetes mellitus	2.9e-05	0.00014	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ADCY5—type 2 diabetes mellitus	2.88e-05	0.000139	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	2.78e-05	0.000135	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	2.76e-05	0.000134	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CCR5—type 2 diabetes mellitus	2.73e-05	0.000132	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CCR5—type 2 diabetes mellitus	2.71e-05	0.000131	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—C3—type 2 diabetes mellitus	2.67e-05	0.000129	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PTGS2—type 2 diabetes mellitus	2.65e-05	0.000128	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—C3—type 2 diabetes mellitus	2.64e-05	0.000128	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PPARG—type 2 diabetes mellitus	2.59e-05	0.000126	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HIF1A—type 2 diabetes mellitus	2.55e-05	0.000123	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—IRS2—type 2 diabetes mellitus	2.54e-05	0.000123	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—INS—type 2 diabetes mellitus	2.54e-05	0.000123	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—AGT—type 2 diabetes mellitus	2.54e-05	0.000123	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	2.52e-05	0.000122	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—IRS2—type 2 diabetes mellitus	2.52e-05	0.000122	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—AGT—type 2 diabetes mellitus	2.51e-05	0.000122	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CALM1—type 2 diabetes mellitus	2.49e-05	0.000121	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—LEP—type 2 diabetes mellitus	2.49e-05	0.00012	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—APOE—type 2 diabetes mellitus	2.49e-05	0.00012	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CALM1—type 2 diabetes mellitus	2.47e-05	0.00012	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—LEP—type 2 diabetes mellitus	2.46e-05	0.000119	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—APOE—type 2 diabetes mellitus	2.46e-05	0.000119	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—APOA1—type 2 diabetes mellitus	2.46e-05	0.000119	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—APOA1—type 2 diabetes mellitus	2.43e-05	0.000118	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.34e-05	0.000114	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ALB—type 2 diabetes mellitus	2.33e-05	0.000113	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.32e-05	0.000113	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—NOS3—type 2 diabetes mellitus	2.23e-05	0.000108	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PIK3R1—type 2 diabetes mellitus	2.23e-05	0.000108	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.22e-05	0.000107	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.2e-05	0.000106	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—INS—type 2 diabetes mellitus	2.12e-05	0.000103	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—INS—type 2 diabetes mellitus	2.1e-05	0.000102	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.09e-05	0.000101	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.07e-05	0.0001	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.05e-05	9.96e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.05e-05	9.95e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.04e-05	9.91e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PTGS2—type 2 diabetes mellitus	2.04e-05	9.87e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.03e-05	9.86e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.03e-05	9.85e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.02e-05	9.81e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.95e-05	9.46e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.93e-05	9.36e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.86e-05	9.03e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.86e-05	9.03e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.84e-05	8.94e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.84e-05	8.94e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—RELA—type 2 diabetes mellitus	1.75e-05	8.5e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—RELA—type 2 diabetes mellitus	1.74e-05	8.41e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.6e-05	7.74e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.58e-05	7.66e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.58e-05	7.66e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.57e-05	7.61e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.57e-05	7.59e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.56e-05	7.54e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.49e-05	7.24e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.48e-05	7.17e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.48e-05	7.17e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.46e-05	7.1e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.45e-05	7.02e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.44e-05	6.96e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—SRC—type 2 diabetes mellitus	1.38e-05	6.68e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—SRC—type 2 diabetes mellitus	1.36e-05	6.61e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.34e-05	6.5e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—AKT1—type 2 diabetes mellitus	1.33e-05	6.45e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.33e-05	6.44e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.23e-05	5.97e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.22e-05	5.91e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.21e-05	5.85e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.2e-05	5.8e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—AKT1—type 2 diabetes mellitus	1.02e-05	4.96e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—IL6—type 2 diabetes mellitus	9.28e-06	4.5e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—IL6—type 2 diabetes mellitus	9.19e-06	4.45e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.56e-06	4.15e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.48e-06	4.11e-05	CbGpPWpGaD
